Can Nanoparticles Become an Alternative to Antibiotics

Rapid growth in the number of pathogens of infectious diseases with multiple drug resistance, including due to the ability of bacteria to form biofilms, greatly complicates the treatment of a number of chronic infectious diseases and the fight against nosocomial infections. Therefore, the search for...

Full description

Saved in:
Bibliographic Details
Published in:Nanobiotechnology Reports (Online) 2023-04, Vol.18 (2), p.153-164
Main Authors: Bolshakova, O. I., Mikhailova, E. A., Zherebyateva, O. O., Miroshnichenko, I. V., Sarantseva, S. V.
Format: Article
Language:English
Subjects:
Antibiotics
Bacteria
Carbon
Chemistry and Materials Science
Drug resistance
Industrial and Production Engineering
Infectious diseases
Machines
Manufacturing
Materials Science
Microorganisms
Nanoparticles
Nanotechnology
Processes
Reviews
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Rapid growth in the number of pathogens of infectious diseases with multiple drug resistance, including due to the ability of bacteria to form biofilms, greatly complicates the treatment of a number of chronic infectious diseases and the fight against nosocomial infections. Therefore, the search for new, alternative, previously unused, selectively acting drugs that are sufficiently effective against pathogenic microorganisms and, at the same time, have low toxicity to the human body becomes especially relevant. From this point of view, nanoparticles, in particular carbon nanoparticles, can become the basis for the development of such drugs. The review presents an analysis of published data on the effect of carbon nanoparticles on bacteria and fungi. The role of the directed functionalization of carbon nanoparticles, which is intended to provide them with the property of selectivity considering the proposed mechanisms of action on various microorganisms, is indicated. Some areas of application of the discussed compounds, in which they can already now compete with antibiotics, are considered.
ISSN:2635-1676
1995-0780
2635-1684
1995-0799
DOI:10.1134/S2635167623700015